Needham & Company Reiterates Buy on Omeros Corp. (OMER) on Mixed OMS103HP Results
Tweet Send to a FriendGet Alerts OMER Hot Sheet
Price: $5.30 +4.33%
Rating Summary:
8 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
8 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade OMER Now!
Needham & Company reiterated their Buy rating and $10 price target on Omeros Corp. (NASDAQ: OMER) following mixed Phase 3 trial results for OMS103HP that missed the primary endpoint but showed a statistically significant impact on early postoperative pain, a secondary endpoint. A second Phase 3 trial in meniscectomy is now consequently planned for 1H13 with pain as a primary endpoint.
"We believe a total of two additional trials, both with pain as the primary endpoint, may be needed for FDA approval," the analyst comments. "We believe OMS103HP has utility in knee surgery, given the known anti-inflammatory activity of its three components. The absence of a consistent, comprehensive positive signal from the Phase 2 and 3 trials, however, suggests that the overall impact may be modest. We nevertheless reiterate our BUY rating based primarily on success of the OMS302 ophthalmology program, which may reach the market in early 2014. Our $10 price target is 25x our 2017 $0.67 EPS estimate, discounted 15%."
For an analyst ratings summary and ratings history on Omeros Corp. click here. For more ratings news on Omeros Corp. click here.
Shares of Omeros Corp. closed at $5.84 yesterday, with a 52 week range of $3.95-$13.45.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"We believe a total of two additional trials, both with pain as the primary endpoint, may be needed for FDA approval," the analyst comments. "We believe OMS103HP has utility in knee surgery, given the known anti-inflammatory activity of its three components. The absence of a consistent, comprehensive positive signal from the Phase 2 and 3 trials, however, suggests that the overall impact may be modest. We nevertheless reiterate our BUY rating based primarily on success of the OMS302 ophthalmology program, which may reach the market in early 2014. Our $10 price target is 25x our 2017 $0.67 EPS estimate, discounted 15%."
For an analyst ratings summary and ratings history on Omeros Corp. click here. For more ratings news on Omeros Corp. click here.
Shares of Omeros Corp. closed at $5.84 yesterday, with a 52 week range of $3.95-$13.45.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Analyst Sees Potential for Omeros' (OMER) OMS824 as FDA Gives Clearance
- Pandora (P) Posts 'Strong Quarter' - Needham & Company
- Toll Bros. (TOL) Estimates/PT Raised at Compass Point
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & Company
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
